Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 6/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574831 | 0.87 | MPO (0.44) | MPOSLC6A4TAAR1IDO1MGLL | |
| SCHEMBL6684267 | 0.83 | MPO (0.46) | MPOSLC6A4TAAR1IDO1MGLL | |
| SCHEMBL4465343 | 0.83 | MPO (0.48) | MPOSLC6A4TAAR1IDO1MGLL | |
| SCHEMBL8611487 | 0.81 | MPO (0.40) | MPOSLC6A4TAAR1IDO1MGLL | |
| SCHEMBL12713548 | 0.81 | MPO (0.40) | MPOSLC6A4TAAR1IDO1MGLL | |
| SCHEMBL13524760 | 0.81 | MPO (0.40) | MPOSLC6A4TAAR1IDO1MGLL | |
| SCHEMBL10025598 | 0.81 | MPO (0.40) | MPOSLC6A4TAAR1IDO1MGLL | |
| SCHEMBL17753758 | 0.81 | MPO (0.40) | MPOSLC6A4TAAR1IDO1MGLL | |
| SCHEMBL10427665 | 0.80 | MPO (0.50) | MPOSLC6A4TAAR1MGLLHTR1A | |
| SCHEMBL4745370 | 0.80 | MPO (0.44) | MPOSLC6A4TAAR1IDO1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101701-B2 | having a hydrophilic group and a silicon-containing alkyl group within molecule; lenses with high oxygen permeability independent from the water content may be obtained, wherein the fumaric acid derivatives is superior in compatibility with the hydrophilic monomer used in combination | MENICON NECT CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| EP-1930338-A1 | Fumaric acid derivates and ophtalmic lenses using the same | E-brain Corporation Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | MENICON NECT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | FAH, FH, AQP4 | MPO 3998/4885SLC6A4 3956/4885TAAR1 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.